Base de dados : MEDLINE
Pesquisa : E07.430 [Categoria DeCS]
Referências encontradas : 471 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 48 ir para página                         

  1 / 471 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29156183
[Au] Autor:Vargas EJ; Rizk M; Bazerbachi F; Abu Dayyeh BK
[Ad] Endereço:Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
[Ti] Título:Medical Devices for Obesity Treatment: Endoscopic Bariatric Therapies.
[So] Source:Med Clin North Am;102(1):149-163, 2018 Jan.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endoscopic bariatric therapies (EBTs) are effective tools for the management of obesity. By mimicking restrictive and bypass surgery physiology, they provide a safe and effective treatment option with the added capabilities of reaching a broader population. Multiple efficacious medical devices, such as intragastric balloons, endoscopic suturing/plication devices, and bypass liners, at various stages of development are available in the United States. EBTs represent the newest addition to a multidisciplinary approach in obesity management. This article reviews several devices' safety and efficacy for primary care providers in the era of evolving obesity treatment.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/métodos
Endoscopia Gastrointestinal/métodos
Balão Gástrico
Obesidade/cirurgia
[Mh] Termos MeSH secundário: Gerenciamento Clínico
Derivação Gástrica/métodos
Gastroplastia/métodos
Seres Humanos
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171121
[St] Status:MEDLINE


  2 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28441654
[Au] Autor:Mojkowska A; Gazdzinski S; Fraczek M; Wylezol M
[Ad] Endereço:Military Institute of Aviation Medicine, Warsaw, Poland.
[Ti] Título:Gastric Ulcer Hemorrhage - a Potential Life-Threatening Complication of Intragastric Balloon Treatment of Obesity.
[So] Source:Obes Facts;10(2):153-159, 2017.
[Is] ISSN:1662-4033
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Some morbidly obese patients do not qualify for bariatric surgery due to general health contraindications. Intragastric balloon treatment might be a therapeutic option in the above-mentioned cases. It can prime super-obese patients with end-stage disease for bariatric surgery. As a neoadjuvant therapy before surgery, it leads to a downstage of the disease by preliminary weight reduction, to an improvement in general health and, in summary, to a reduction of the perioperative risk. It is generally considered to be a safe method. However, due to the wide range of possible complications and unusual symptoms after intragastric balloon treatment, an interdisciplinary, instead of only a surgical or endoscopic, treatment and follow-up might be recommended in these patients. CASE REPORT: We here describe a potential life-threatening complication in the form of gastric bleeding as a consequence of intragastric balloon treatment and simultaneous aspirin taking and Helicobacter pylori infection. CONCLUSION: There have been reports of some complications of intragastric balloon treatment. However, to the best of our knowledge there were no reports concerning life-threatening hemorrhage from gastric ulcer.
[Mh] Termos MeSH primário: Balão Gástrico/efeitos adversos
Hemorragia Gastrointestinal/etiologia
Obesidade Mórbida/cirurgia
Úlcera Gástrica/etiologia
[Mh] Termos MeSH secundário: Adulto
Aspirina/administração & dosagem
Cirurgia Bariátrica/métodos
Infecções por Helicobacter
Helicobacter pylori
Seres Humanos
Masculino
Úlcera Gástrica/microbiologia
Perda de Peso
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1159/000456666


  3 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28440517
[Au] Autor:Huang S; Zhang J; Dong Z; Wang C
[Ti] Título:[Efficacy and future of endoscopic bariatric surgery in the treatment of obesity and metabolic diseases].
[So] Source:Zhonghua Wei Chang Wai Ke Za Zhi;20(4):383-387, 2017 Apr 25.
[Is] ISSN:1671-0274
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:The emerging endoscopic technologies are proved to be effective treatments for obesity in selected patients and to offer the potential advantages of reduced invasiveness, reversibility and repeatability. From the view of operation principle, endoscopic technologies can be classified as restrictive procedure, malabsorption procedure and endoscopic revision of gastric bypass. Restrictive procedures include intragastric balloon, aspiration therapy, endoscopic sleeve gastroplasty (ESG) and transoral gastroplasty. Intragastric balloon employs space occupying, volume restriction and satiety mechanisms, which is superior to drugs and lifestyle change, but shorter than sleeve and bypass surgery. Aspiration therapy is similar to standard percutaneous endoscopic gastrostomy, while there are no available data regarding the obesity and metabolic improvement. Compared with traditional bariatric surgery, ESG does not excise gastric tissue with less complications and without weight regain, but it can not be used as an independent operation still now. Transoral gastroplasty is rarely applied clinically whose efficacy and long-term complications need further studies. Malabsorption surgery includes endoscopic duodenojejunal bypass sleeve (EDJBS) and endoscopic gastroduodenojejunal bypass sleeve(EGDJBS). EDJBS may have the similar mechanism like bypass reducing the blood glucose. Even with obvious effect of weight loss, EDJBS has high morbidity of complications and requirements of the skilled operators. EGDJBS, which imitates bypass anatomy changes and belongs to the mixed operation, should be superior to the above procedures in reducing weight theoretically, but due to the lack of clinical data, its short-term and long-term efficacy still need further clinical observation. As compared to the complexity and risks associated with telescopic surgical revision, endoscopic suturing has been confirmed as less invasive and safer for stomal revisions, while its long-term efficacy of reducing weight and improvement of diabetes are not yet clear. Even if long-term efficacy of reducing weight and morbidity of complication in endoscopic bariatric surgery are still indefinite, and clinical trial researches of large sample and long-term follow-up are absent, with the development of endoscopic skill and the gradual clinical application, endoscopic bariatric surgery will provide a new option for the patients of obesity and metabolic diseases.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/efeitos adversos
Cirurgia Bariátrica/métodos
Cirurgia Bariátrica/estatística & dados numéricos
Cirurgia Bariátrica/tendências
Endoscopia/efeitos adversos
Endoscopia/métodos
Endoscopia/estatística & dados numéricos
Doenças Metabólicas/cirurgia
Obesidade/cirurgia
Resultado do Tratamento
[Mh] Termos MeSH secundário: Gerenciamento Clínico
Balão Gástrico/estatística & dados numéricos
Derivação Gástrica/efeitos adversos
Derivação Gástrica/métodos
Derivação Gástrica/estatística & dados numéricos
Gastroplastia/efeitos adversos
Gastroplastia/métodos
Gastroplastia/estatística & dados numéricos
Seres Humanos
Reoperação/efeitos adversos
Reoperação/métodos
Reoperação/estatística & dados numéricos
Estomas Cirúrgicos/patologia
Estomas Cirúrgicos/estatística & dados numéricos
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE


  4 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28421456
[Au] Autor:Laing P; Pham T; Taylor LJ; Fang J
[Ad] Endereço:Department of Gastroenterology and Hepatology, University of Utah, Salt Lake City, UT, USA.
[Ti] Título:Filling the Void: A Review of Intragastric Balloons for Obesity.
[So] Source:Dig Dis Sci;62(6):1399-1408, 2017 Jun.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endoscopic bariatric therapies are predicted to become much more widely used in North America for obese patients who are not candidates for bariatric surgery. Of all the endoscopic bariatric therapies, intragastric balloons (IGBs) have the greatest amount of clinical experience and published data supporting their use. Three IGBs are FDA approved and are now commercially available in the USA (Orbera, ReShape Duo, and Obalon) with others likely soon to follow. They are generally indicated for patients whose BMI ranges from 30 to 40 mg/kg and who have failed to lose weight with diet and exercise. IGBs have been shown to be safe, effective, and relatively straightforward to place and remove. Accommodative symptoms commonly occur within the initial weeks post-placement; however, major complications are rare. Gastric ulceration can occur in up to 10% of patients, while balloon deflation with migration and bowel obstruction occurs in <1% of patients. The effectiveness of the Orbera and ReShape Duo IGBs ranges from 25 to 50% EWL (excess weight loss) after 6 months of therapy. The use of IGBs is likely to grow dramatically in the USA, and gastroenterologists and endoscopists should be familiar with their indications/contraindications, efficacy, placement/removal, and complications.
[Mh] Termos MeSH primário: Bariatria/instrumentação
Balão Gástrico
Obesidade/terapia
[Mh] Termos MeSH secundário: Bariatria/efeitos adversos
Contraindicações
Balão Gástrico/efeitos adversos
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-017-4566-2


  5 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28361843
[Au] Autor:Mosli MM; Elyas M
[Ad] Endereço:Department of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
[Ti] Título:Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
[So] Source:Saudi J Gastroenterol;23(2):117-122, 2017 Mar-Apr.
[Is] ISSN:1998-4049
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Intragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction. PATIENTS AND METHODS: A retrospective analysis of all cases treated with IGB with or without Liraglutide was performed. Outcomes were statistically compared. RESULTS: A total of 108 patients were included; 64 were treated with IGB alone and 44 with IGB + Liraglutide. Six months after removing IGB, patients treated with IGB + Liraglutide had a higher mean weight loss post treatment completion (10.2 ± 6.7 vs. 18.5 ± 7.6, P = <0.0001) than those treated with IGB alone. After adjusting for covariates, patients treated with IGB alone demonstrated a higher mean body weight loss at the time of IGB removal (coefficient 7.71, 95% CI = 4.78-10.63), and a higher odds of treatment success 6 months post IGB removal (OR = 5.74, 95% CI = 1.79-188.42). Baseline body mass index appeared to be a significant predictor of mean body weight loss at the time of balloon removal. CONCLUSIONS: Adding Liraglutide to IGB does not appear to decrease the risk of weight regain 6 months post IGB removal.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/instrumentação
Liraglutida/administração & dosagem
Obesidade Mórbida/terapia
[Mh] Termos MeSH secundário: Adulto
Cirurgia Bariátrica/métodos
Índice de Massa Corporal
Terapia Combinada
Feminino
Balão Gástrico
Seres Humanos
Liraglutida/uso terapêutico
Masculino
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
839I73S42A (Liraglutide)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE
[do] DOI:10.4103/1319-3767.203362


  6 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28292405
[Au] Autor:Sampath K; Rothstein RI
[Ad] Endereço:Section of Gastroenterology and Hepatology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address: kartik.sampath@hitchcock.org.
[Ti] Título:Selected Endoscopic Gastric Devices for Obesity.
[So] Source:Gastrointest Endosc Clin N Am;27(2):267-275, 2017 Apr.
[Is] ISSN:1558-1950
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This article focuses on the stomach target devices that are currently in various stages of development. Approved intragastric balloons, devices targeting small bowel and aspiration techniques, are described in other contributions to this issue. Bariatric endoscopic devices targeting the stomach directly alter gastric physiology and promote weight loss by potentially changing functional gastric volume, gastric emptying, gastric wall compliance, neurohormonal signaling, and, thereby, satiety. Many stomach-targeting devices are on the horizon for clinical use, and further study will determine the safety and efficacy for clinical use.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/instrumentação
Gastroscopia/instrumentação
Obesidade/cirurgia
[Mh] Termos MeSH secundário: Cirurgia Bariátrica/métodos
Balão Gástrico
Gastroscopia/métodos
Seres Humanos
Escleroterapia/métodos
Estômago/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE


  7 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28292403
[Au] Autor:Papademetriou M; Popov V
[Ad] Endereço:Gastroenterology, New York University School of Medicine, 220 First Avenue, New York, NY 10016, USA.
[Ti] Título:Intragastric Balloons in Clinical Practice.
[So] Source:Gastrointest Endosc Clin N Am;27(2):245-256, 2017 Apr.
[Is] ISSN:1558-1950
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cost-effective therapies to address the growing epidemic of obesity are a leading priority in modern medicine. Intragastric balloons (IGBs) are one such option, with increased effectiveness compared with pharmacotherapy and lifestyle and a lower rate of adverse events than bariatric surgery. IGBs are endoscopically placed or swallowed space-occupying devices in the stomach. Three IGB systems were approved in 2015 to 2016 by the Food and Drug Administration for use in the United States, with more devices nearing approval. This paper reviews the adverse events and efficacy of IGBs, and practice setup, management of common complications, and dietary advice for patients.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/métodos
Balão Gástrico/efeitos adversos
Gastroscopia/efeitos adversos
Obesidade/cirurgia
Complicações Pós-Operatórias/terapia
[Mh] Termos MeSH secundário: Cirurgia Bariátrica/efeitos adversos
Gastroscopia/métodos
Seres Humanos
Equipe de Assistência ao Paciente
Complicações Pós-Operatórias/etiologia
Estômago/cirurgia
Resultado do Tratamento
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE


  8 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28222644
[Au] Autor:Chen H; Yang YL; Xu M; Shi ZH; He X; Sun XM; Luo XY; Chen GQ; Zhou JX
[Ad] Endereço:1 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
[Ti] Título:Use of the injection test to indicate the oesophageal balloon position in patients without spontaneous breathing: a clinical feasibility study.
[So] Source:J Int Med Res;45(1):320-331, 2017 Feb.
[Is] ISSN:1473-2300
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objective To investigate the clinical feasibility of the injection test for balloon placement during oesophageal pressure measurement in patients without spontaneous breathing. Methods The injection test was performed in 12 mechanically ventilated patients under deep sedation and paralysis. During withdrawal of the balloon from the stomach and air injection into the gastric lumen of the catheter, the presence of the injection test wave in the balloon pressure tracing indicated that the whole balloon was positioned above the lower oesophageal sphincter (LES). The positive pressure occlusion test was performed at different balloon positions. Results In each patient, the injection test wave appeared at a distinct balloon depth, with a mean ± standard deviation of 41.9 ± 3.3 cm and range from 37 cm to 47 cm. The optimal ratio of changes in the balloon and airway pressure (0.8-1.2) during the positive pressure occlusion test was obtained when the balloon was located 5 cm and 10 cm above the LES in nine (75%) and three (25%) patients, respectively. Conclusions The injection test is feasible for identification of the whole balloon position above the LES during passive ventilation. The middle third of the oesophagus might be the optimal balloon position.
[Mh] Termos MeSH primário: Balão Gástrico
Intubação Gastrointestinal/métodos
Intubação Intratraqueal/métodos
Respiração com Pressão Positiva/instrumentação
Paralisia Respiratória/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Anestesia Geral
Esfíncter Esofágico Inferior
Feminino
Seres Humanos
Intubação Gastrointestinal/instrumentação
Intubação Intratraqueal/instrumentação
Masculino
Meia-Idade
Respiração com Pressão Positiva/métodos
Pressão
Estudos Prospectivos
Paralisia Respiratória/fisiopatologia
Estômago
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.1177/0300060516679776


  9 / 471 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28147221
[Au] Autor:Abu Dayyeh BK; Edmundowicz S; Thompson CC
[Ad] Endereço:Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: abudayyeh.barham@mayo.edu.
[Ti] Título:Clinical Practice Update: Expert Review on Endoscopic Bariatric Therapies.
[So] Source:Gastroenterology;152(4):716-729, 2017 Mar.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Multiple endoscopic bariatric therapies (EBTs) currently are being evaluated or are in clinical use in the United States. EBTs are well positioned to fill an important gap in the management of obesity and metabolic disease. The purpose of this expert review is to update gastroenterologists on these therapies and provide practice advice on how to incorporate them into clinical practice. METHODS: The evidence reviewed in this work is a distillation of comprehensive search of several English-language databases and a manual review of relevant publications (including systematic reviews and meeting abstracts). Best Practice Advice 1: EBTs should be considered in patients with obesity who have been unsuccessful in losing or maintaining weight loss with lifestyle interventions. Best Practice Advice 2: EBTs can be used in patients with severe obesity as a bridge to traditional bariatric surgery. They also can be used as a bridge to allow unrelated interventions that are unable to be performed because of weight limits (ie, orthopedic surgery, organ transplantation). Best Practice Advice 3: Clinicians should use EBTs as part of a structured weight loss program that includes dietary intervention, exercise therapy, and behavior modification, in both the active weight loss phase and the long-term maintenance phase. Best Practice Advice 4: Clinicians should screen all potential EBT candidates with a comprehensive evaluation for medical conditions, comorbidities, and psychosocial or behavioral patterns that contribute to their condition before enrolling patients in a weight loss program that includes EBTs. Best Practice Advice 5: Clinicians incorporating EBTs into their clinical practice should follow up patients prospectively to capture the impact of the EBT program on weight and weight-related comorbidities, and all related adverse outcomes. Poor responders should be identified and offered a detailed evaluation and alternative therapy. Best Practice Advice 6: Clinicians embarking on incorporating EBTs into their clinical practice should have a comprehensive knowledge of the indications, contraindications, risks, benefits, and outcomes of individual EBTs, as well as a practical knowledge of the risks and benefits of alternative therapies for obesity. Best Practice Advice 7: Institutions should establish specific guidelines that are applied consistently across disciplines for granting privileges in EBTs that reflect the necessary knowledge and technical skill a clinician must achieve before being granted privileges to perform these procedures.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/métodos
Endoscopia Gastrointestinal
Obesidade/terapia
[Mh] Termos MeSH secundário: Competência Clínica
Contraindicações
Medicina Baseada em Evidências
Balão Gástrico
Seres Humanos
Política Organizacional
Seleção de Pacientes
Programas de Redução de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE


  10 / 471 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28117361
[Au] Autor:Popov VB; Ou A; Schulman AR; Thompson CC
[Ad] Endereço:NYU Langone Medical Center and VA NY Harbor Healthcare System, New York University School of Medicine, New York, USA.
[Ti] Título:The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis.
[So] Source:Am J Gastroenterol;112(3):429-439, 2017 Mar.
[Is] ISSN:1572-0241
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:ObjectivesTherapies less invasive than surgery and more effective than lifestyle and pharmacotherapy are needed to contend with the obesity epidemic. Intragastric balloons (IGBs) are a minimally invasive endoscopic weight loss method recently approved for use in the US. The purpose of the study is to assess the effect of IGBs on metabolic outcomes associated with obesity.MethodsMEDLINE, Embase, and Cochrane Database were searched through July 2016. Dual extraction and quality assessment of studies using Cochrane risk of bias tool were performed independently by two authors. Primary outcomes included the change from baseline in metabolic parameters. Secondary outcomes included resolution and/or improvement in metabolic co-morbidities and association with baseline parameters.Results10 randomized controlled trials (RCT) and 30 observational studies including 5,668 subjects were analyzed. There was moderate-quality evidence for improvement in most metabolic parameters in subjects assigned to IGB therapy as compared to conventional non-surgical therapy in RCTs: mean difference (MD) in fasting glucose change: -12.7 mg/dl (95% confidence interval (CI) -21.5, -4); MD in triglycerides: -19 mg/dl (95% CI -42, 3.5); MD in waist circumference: -4.1 cm (95% CI -6.9, -1.4); MD in diastolic blood pressure: -2.9 mm Hg (95% CI -4.1, -1.8). The odds ratio for diabetes resolution after IGB therapy was 1.4 (95% CI 1.3, 1.6). The rate of serious adverse events was 1.3%.ConclusionsIGBs are more effective than diet in improving obesity-related metabolic risk factors with a low rate of adverse effects, however the strength of the evidence is limited given the small number of participants and lack of long-term follow-up.
[Mh] Termos MeSH primário: Endoscopia do Sistema Digestório
Balão Gástrico
Obesidade/cirurgia
Complicações Pós-Operatórias/epidemiologia
[Mh] Termos MeSH secundário: Glicemia/metabolismo
Pressão Sanguínea
Comorbidade
Diabetes Mellitus Tipo 2/epidemiologia
Diabetes Mellitus Tipo 2/metabolismo
Seres Humanos
Hipertensão/epidemiologia
Hipertrigliceridemia/epidemiologia
Hipertrigliceridemia/metabolismo
Obesidade/epidemiologia
Obesidade/metabolismo
Resultado do Tratamento
Triglicerídeos/metabolismo
Circunferência da Cintura
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Triglycerides)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170620
[Lr] Data última revisão:
170620
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170125
[St] Status:MEDLINE
[do] DOI:10.1038/ajg.2016.530



página 1 de 48 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde